新股速遞 | 歐康維視生物-B入場費7,403.87港元，14位基石鎖定近50%的發行股份
uSMART友信智投6月29日消息，歐康維視生物-B今日起招股，從IPO角度而言，該股與近期大賺新股康基醫療、康方生物-B、沛嘉醫療-B有諸多相似點：明星保薦人、基石星光熠熠、生物醫藥板塊。
【一】招股簡況
【二】申請檔位
【三】公司看點
1）引入14位明星基石投資者：Fidelity International(富達基金）、Alpha Profit Holdings Limited、TLS Beta Pte. Ltd、General Atlantic Singapore OT Pte. Ltd、Lake Bleu Prime(清池資本）、貝萊德基金、Boyu Capital Opportunities Master Fund、SCC Growth、Cormorant、OrbiMed Funds(奧博資本）、Hudson Bay Master Fund LTD、Rock Springs Capital Management LP、HBM Healthcare、Octagon Investments。
其中的富達基金、清池資本、奧博資本、貝萊德基金、Cormorant，也是暗盤暴升87.68%的康基醫療的基石投資者。
2）B類生物醫藥股行情火爆：目前已有18隻該類新股上市，不管從上市首日還是後續表現來看，都深受資本市場的喜愛，比如2018年上市的信達生物、君實生物、康希諾生物累計升幅分別達到了3倍、2倍和9倍。自2019年底以來，累計上市的B類股有6隻，更是出現了熱烈行情。
3）摩根士丹利、高盛聯合保薦：均是港股IPO市場的明星保薦機構，近兩年的業績非常突出，曾聯手保薦諾誠健華、基石藥業、藥明康得、信達生物、美團等，升幅喜人。其中摩根士丹利共保薦26隻新股，首日上升概率81%，代表作沛嘉醫療。高盛保薦19隻新股，首日上升概率73.7%，代表作啟明醫療。
4）眾多頂級機構加持：IPO前進行兩輪融資，共集資2億美元，投後估值4.8億美元。投資者包括6 Dimensions、Boyu Capital、淡馬錫、3W Fund、Cormorant Fund等，大多都是全球領先的醫療風險投資基金，投資的公司包括港股熱門的醫藥股，包括基石藥業、翰森製藥、信達生物、藥明康得、沛嘉醫療等。
風險提示：
歷史資料僅供參考，不代表投資建議。IPO有風險，投資者需要閱讀招股書後做出是否申購的選擇。
點擊可閱讀《歐康維視生物-B招股書》原文PDF。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
